Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass (COMP) stock fell 2.4% in Friday midday trading following a report that Senator Elizabeth Warren (D-MA) questioned ...

Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) stock surged 33.7% on Tuesday following the announcement of highly statistically significant results from its second Phase 3 trial for COMP360, a ...

If you are wondering whether Compass is still attractively priced or already reflects the story in its share price, the starting point is to look closely at what the current market value implies. The ...

Compass Inc. stock (NYSE: COMP) has been experiencing significant pressure, having declined over 15% within the last week, while the S&P 500 only fell by 0.6%. The catalyst for this decline: Compass’s ...

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

Compass Therapeutics (CMPX) is back on investors’ radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing ...